Megluminantimonate

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

IndicationThis section has been translated automatically.

Dosage and method of useThis section has been translated automatically.

Remember! Maximum dose 850 mg/day!

  • Visceral Leishmaniasis: 20 mg/kg bw/day for at least 20 days (until no more parasites can be detected).
  • Cutaneous leishmaniasis (except L. aethiopica, brasiliensis, guyanamensis):
    • Local therapy: Injection of 1-3 ml under the ulcer, possibly 1-2 scds at intervals of 1-2 days.
    • Systemic: 10-20 mg/kg bw/day until the smears are negative and then another 3 days.
  • Cutaneous leishmaniasis (L. brasiliensis): 20 mg/kg bw/day until the lesion is healed (max. 4 weeks).
  • Mucocutaneous leishmaniasis: 20 mg/kg bw/day until the smear is negative (max. 4 weeks).
  • Diffuse cutaneous leishmaniasis: 20 mg/kg bw/day until clinical improvement occurs (usually for months).

PreparationsThis section has been translated automatically.

Glucantime (available through the international pharmacy).

Authors

Last updated on: 29.10.2020